YCBD
cbdMD Inc
AMEX: YCBD · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.78
-3.53% today
Updated 2026-06-05
Market cap
$7.51M
P/E ratio
0.29
P/S ratio
0.38x
EPS (TTM)
$2.46
Dividend yield
—
52W range
$0 – $3
Volume
1.7M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
4.7
Growth
C7.0
Quality
B+2.0
Profitability
F7.0
Valuation
B+6/9
Piotroski F-Score
Moderate
-21.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$2.00
+155.04%
12-Month target
$0.74
-5.64%
Intrinsic (DCF)
$0.84
Margin of safety
+10.27%
Price chart
Stock snapshot
Strengths
+ Revenue growth 18.80% QoQ
+ 10.27% below intrinsic value
+ Debt/equity 0.04x — low leverage
Risks
- Altman Z -21.17 — distress zone
- Thin margins at -13.30%
- Negative free cash flow $-728250.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $35.40M | $24.16M | $19.48M | $19.19M | $19.98M |
| Net income | $-70.08M | $-22.94M | $-3.70M | $-2.04M | $-797978.00 |
| EPS | — | — | — | — | $2.46 |
| Free cash flow | $-15.66M | $-4.60M | $-642807.00 | $-1.64M | $-728250.00 |
| Profit margin | -197.96% | -94.96% | -18.99% | -10.63% | -13.30% |
Peer comparison
Smart narrative
cbdMD Inc trades at $0.78. representing a P/E of 0.29x trailing earnings. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -21.17, it sits in the distress. TTM revenue stands at $19.98M. with profit margins at -13.30%. Our DCF model estimates intrinsic value at $0.84.
Frequently asked questions
What is cbdMD Inc's stock price?
cbdMD Inc (YCBD) trades at $0.78, on a P/E of 0.3x and a P/S of 0.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is cbdMD Inc overvalued?
cbdMD Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $0.84 versus the $0.78 price, a 10.3% margin of safety on a cash flow basis.
What is the price target of cbdMD Inc (YCBD)?
The 12-month analyst consensus target is $2.00, about 155.0% above the current $0.78. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of cbdMD Inc (YCBD)?
Our DCF model estimates intrinsic value at $0.84, a +10.3% margin of safety versus today's $0.78. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is cbdMD Inc's revenue?
cbdMD Inc's trailing twelve-month revenue is $19.98M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
cbdMD Inc's Altman Z-Score is -21.17, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio0.38x
ROE-28.61%
Beta2.17
50D MA$0.79
200D MA$0.87
Shares out0.01B
Float0.01B
Short ratio—
Avg volume1.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—